Tag: Preсlinical Studies

Kineta starts drug development collaboration with Genentech

Kineta announced that it has entered into an exclusive option and license agreement with Genentech to develop Kineta's α9/α10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain.

Chinese biotech Biocytogen received $65 million investment

CMB International Capital Corporation, a wholly-owned subsidiary of China Merchants Bank, provided a $65 million budgeting for Beijing Biocytogen, a gene targeted animal model and service supplier.

Frontage Laboratories acquired Concord Biosciences

Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.

Takeda sells worldwide rights for a genetic disorder drug to Rhythm Pharma

Rhythm Pharmaceuticals, a biopharmaceutical company, announced that it has acquired exclusive, worldwide rights from Takeda Pharmaceutical Company to develop and commercialize a rare genetic disorder drug.

Innate Biologics and The Wistar Institute started a research collaboration

Innate Biologics is working with Wistar to develop a first-of-its-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways.

Scientists from Kazan developed a drug for muscle weakness

Biologists from Kazan have developed a new drug capable of suppressing myasthenia (muscle weakness) without inducing strong side effects. The scientists tested new drug in rats and human bladder tissue samples.

Scientists from Australia and Wales developed a new vaccine production platform

A team led by Associate Professor John Miles from James Cook University and Cardiff University’s Professor Andrew Sewell describe how they engineered a new vaccine production platform and built a fully synthetic flu vaccine.

Bavarian Nordic set up a partnership with US Department of Defense

Bavarian Nordic announced the signing of a new alliance with the US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus—a rare, but potentially deadly mosquito-borne illness.

Citoxlab announced the acquisition of Solvo Biotechnology

Citoxlab Group, a leading non-clinical CRO, entered into a definitive agreement to acquire Solvo Biotechnology, a CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions.

BioNeuroPharma starts collaboration with Cuban Neuroscience Center

BioNeuroPharma, a participant of SKOLKOVO biomed cluster, reached an agreement with the Cuban Neuroscience Center (CNEURO) on collaboration in the development of potential drugs for treatment of Alzheimer's disease.

A drug for restoring the liver function successfully passed preclinical tests

The scientists from the Siberian State Medical University are completing the preclinical studies of a unique drug that normalizes the liver detox function and has no obvious undesirable pharmacological properties

More than 12 billion rubles to be invested in the pharma industry of Irkutsk region

More than 12 billion rubles will be allocated, under the public-private partnership, to three projects aimed at developing the pharmaceutical industry in the Irkutsk region

Rani Therapeutics received funding for clinicals trials of its innovative pill

digital drug
Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery, announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials

Obninsk laboratory will speed up the market launch of the modern drugs

A laboratory for early studies of pharmaceuticals intended to treat cancer will be opened in the city of Obninsk, Kaluga region. It will allow to accelerate the market launch of the modern drugs manuf...

A pharmaceutical technopark is planned to be established in the Baikal region

A meeting of Scientific Coordination Council under the Governor of the Irkutsk region was held in the Government of the Irkutsk region

BioMed X and Boehringer Ingelheim initiated new joint research group

BioMed X announced the start of a new joint research group with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg